The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
What is the benefit of adding pevonedistat to azacitidine in patients with high-risk MDS or AML?
Featured:
Lionel AdesDuring the American Society of Clinical Oncology (ASCO) Annual Meeting, the MDS Hub was delighted to speak to Lionel Ades, Saint-Louis Hospital, Paris, FR. We asked: what is the benefit of adding pevonedistat to azacitidine in patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)?
What is the benefit of adding pevonedistat to azacitidine in patients with high-risk MDS or AML?
In this video, Lionel Ades describes the results of the phase II study that evaluated this combination in patients who had not previously received hypomethylating agents and were ineligible for stem cell transplant. He describes the event-free survival results of the 120 patients enrolled in the study as well as the overall survival and duration of response in the three patient populations: high-risk MDS, high-risk AML or low blast AML.